As Tocagen heads into a reverse merger with privately held Forte Biosciences, San Diego-based Denovo Biopharma swooped in to snap up that company’s retroviral replicating vector platform (RRV), including an asset that stumbled in a Phase III study that Denovo believes still has some life.
Dublin, Ireland-based Avadel Pharma announced positive topline data from the company’s pivotal Phase III REST-ON clinical trial of FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Axsome Therapeutics announced that the company’s AXS-05 met the primary endpoint in the ADVANCE-1 Phase II/III clinical trial for agitation in patients with Alzheimer’s disease.
Bristol-Myers Squibb and Exelixis are eying potential approval of a combination therapy for renal cell carcinoma following results from a late-stage study that showed a combination of Opdivo and Cabometyx met the primary endpoint of progression-free survival.
A recent study published in JAMA Oncology found that although about a third of cancer clinical trials failed to meet their primary endpoints, at oncology meetings they tend to be spun in a positive light.
Merck’s Keytruda Hits Coprimary Endpoint Early in Colorectal Cancer Trial
Blockbusters, Checkpoint Inhibitors, Chemotherapy, Clinical Trials, Colorectal Cancer, Data Monitoring Committee (DMC), Metastatic Colorectal Cancer (mCRC), Overall Survival (OS), Primary Endpoints, Progression-Free Survival (PFS), R&D, TherapeuticsMerck’s checkpoint inhibitor Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.
Treatment with Stelara is resulting in positive outcomes for patients with Crohn’s disease, as Janssen Pharmaceutical said 79% of patients in a late-stage trial showed a clinical response to the medication and 67% were in clinical remission.